ACMSD

OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Eli Lilly and Company, IND, NYSE, LXR, DSM-IV codes, Obesity, LLY, MD, Doctor of Philosophy, Agonal respiration, Commercialization, NASH, Cancer, ACMSD, Series, Patient, Pharmaceutical industry, Nursing, Saṃsāra

The financing, which will support the advancement of OrsoBio’s obesity-focused portfolio, was co-led by Longitude Capital and Enavate Sciences.

Key Points: 
  • The financing, which will support the advancement of OrsoBio’s obesity-focused portfolio, was co-led by Longitude Capital and Enavate Sciences.
  • OrsoBio will utilize the Series A funding to advance the development of its innovative portfolio of four programs focused on obesity and associated metabolic disorders.
  • ACMSD inhibitor (aminocarboxymuconate semialdehyde decarboxylase inhibitor): Selection of a development candidate for potential treatment of metabolic and inflammatory liver and kidney disorders and advancement of IND-enabling activities.
  • “We are grateful for the continued trust in our team and commitment to our mission to improve clinical outcomes in patients with obesity and associated metabolic disorders.

Parkinson's Foundation Receives Grant to Fund Critical Research, Genetic Testing and Counseling

Retrieved on: 
Tuesday, March 7, 2023
Encephalitis, Meyers, Parkinson's disease, Barrow Neurological Institute, Candid (organization), Genetics, Research, ACMSD, Pat Simon, DRS, Senior counsel, PD, Hope, Genetic testing, Parkinson's Foundation, Doctor of Philosophy, Translational neuroscience, Pharmaceutical industry, Palladium, Barrow

NEW YORK and MIAMI, March 7, 2023 /PRNewswire/ -- The Parkinson's Foundation has received a grant of nearly $800,000 from the Pat Simone Charitable Foundation, Inc. to fund research at Barrow Neurological Institute, which includes the Muhammad Ali Parkinson Center, a Parkinson's Foundation Center of Excellence. The grant aims to improve the lives of people with Parkinson's disease (PD) in Arizona by funding promising scientists conducting innovative research and increasing local participation in PD GENEration: Mapping the Future of Parkinson's Disease.

Key Points: 
  • The work at Barrow has the potential to improve the lives of the local PD community—an estimated 18,000 people who live with PD in Arizona.
  • Dr. Meyers received a prestigious Parkinson's Foundation Postdoctoral Fellowship for Basic Scientists in support of this study.
  • Additionally, funding will expand local participation in PD GENEration, offering genetic testing and counseling (in English and Spanish) at no cost for people with PD in Arizona.
  • Genetic testing can help people with PD and their clinicians identify whether they may qualify for enrollment in certain clinical trials.